Literature DB >> 11479425

Reliability of PCR-based detection of occult tumour cells: lessons from real-time RT-PCR.

N Max1, M Willhauck, K Wolf, F Thilo, U Reinhold, M Pawlita, E Thiel, U Keilholz.   

Abstract

For the molecular detection of rare tumour cells in clinical samples, real-time reverse transcription-polymerase chain reaction (RT-PCR) offers two important advantages over conventional RT-PCR assays: the results are quantitative and, perhaps more importantly, it facilitates exact sensitivity controls on a per sample basis as well as exact comparison of different assay protocols. We report here on quantitative results obtained with different protocols for RNA isolation and cDNA synthesis for amplification of beta2-microglobulin transcripts using the light cycler system. Furthermore, housekeeping gene-specific PCRs were compared with PCRs specific for an artificial transcript (internal standard) detected simultaneously at a level comparable to the wild-type sequence. Artificial tyrosinase transcripts derived from a vector construct stably transfected into a human lymphoma cell line were used as a model to test the usefulness of artificial internal standards as an alternative to housekeeping genes. The highest RNA yields were obtained using a combination of phenol-chloroform extraction and the High Pure RNA Isolation Kit. Analysing beta2-microglobulin transcript-specific RT-PCRs, the highest sensitivity was obtained for cDNAs generated with Omniscript reverse transcriptase and oligo-p(dT)15 primer. Regarding patient blood samples, RT-PCRs specific for beta2-microglobulin, porphobilinogen deaminase and artificial tyrosinase transcripts provided quantitative data for all, for 18 out of 21, and for 10 out of 21 samples, respectively. Quantification of beta2-microglobulin transcripts by the light cycler system defined the protocol revealing the highest cDNA quality. Comparisons of quantitative data from RT-PCRs specific for beta2-microglobulin, porphobilinogen deaminase and artificial tyrosinase transcripts enabled us to determine a close range for crossing points within which sufficient cDNA quality can be guaranteed, even for the detection of rare transcripts. PCRs specific for the artificial internal standard are ideally suited for cDNA quality assessment on a per sample basis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11479425     DOI: 10.1097/00008390-200108000-00007

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  5 in total

1.  Specific detection of cytokeratin 20-positive cells in blood of colorectal and breast cancer patients by a high sensitivity real-time reverse transcriptase-polymerase chain reaction method.

Authors:  Giuliana Giribaldi; Simone Procida; Daniela Ulliers; Franca Mannu; Roberta Volpatto; Giorgia Mandili; Laura Fanchini; Oscar Bertetto; Gianruggero Fronda; Luigi Simula; Elena Rimini; Giovanni Cherchi; Lisa Bonello; Milena Maria Maule; Francesco Turrini
Journal:  J Mol Diagn       Date:  2006-02       Impact factor: 5.568

2.  Critical evaluation of real-time reverse transcriptase-polymerase chain reaction for the quantitative detection of cytokeratin 20 mRNA in colorectal cancer patients.

Authors:  Nadia Dandachi; Marija Balic; Stefanie Stanzer; Michael Halm; Margit Resel; Thomas Anton Hinterleitner; Hellmut Samonigg; Thomas Bauernhofer
Journal:  J Mol Diagn       Date:  2005-11       Impact factor: 5.568

3.  Impact of circulating free tumor cells in the peripheral blood of colorectal cancer patients during laparoscopic surgery.

Authors:  Wei-Shone Chen; Ming-Yi Chung; Jin-Hwang Liu; Jacqueline Ming Liu; Jen-Kou Lin
Journal:  World J Surg       Date:  2004-06       Impact factor: 3.352

4.  Detection limits of several commercial reverse transcriptase enzymes: impact on the low- and high-abundance transcript levels assessed by quantitative RT-PCR.

Authors:  Jean-Philippe Levesque-Sergerie; Mathieu Duquette; Catherine Thibault; Louis Delbecchi; Nathalie Bissonnette
Journal:  BMC Mol Biol       Date:  2007-10-22       Impact factor: 2.946

Review 5.  Issues affecting molecular staging in the management of patients with melanoma.

Authors:  G Palmieri; M Casula; M C Sini; P A Ascierto; A Cossu
Journal:  J Cell Mol Med       Date:  2007 Sep-Oct       Impact factor: 5.310

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.